We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B Turnover 32.84%
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+109.07%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$510M
AUM Growth
+$233M
Cap. Flow
+$45.1M
Cap. Flow %
8.85%
Top 10 Hldgs %
42.94%
Holding
56
New
7
Increased
29
Reduced
8
Closed
9
Avg Time Held
1.2 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$9.74M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.11M
3
FOCL icon
EDAP TMS S.A.
FOCL
+$6.97M
4
FLXN icon
Flexion Therapeutics, Inc.
FLXN
+$5.24M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.4M

Top Sells

Rank Stock Value
1
TVRD icon
Tvardi Therapeutics
TVRD
+$8.04M
2
CYTK icon
Cytokinetics
CYTK
+$7.4M
3
SWAV icon
Shockwave Medical, Inc. Common Stock
SWAV
+$4.79M
4
THOR icon
Synthorx, Inc. Common Stock
THOR
+$2.93M
5
NXTC icon
NextCure
NXTC
+$2.62M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FLXN icon
26
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.6M 1.69%
415,500
+310,500
+296% +$5.24M
2019 Q3
1 quarter
BPMC icon
27
DELISTED
Blueprint Medicines
BPMC
$8M 1.57%
100,000
-5,000
-5% -$374K
2015 Q3
17 quarters
ZYME icon
28
Zymeworks
ZYME
$1.82B
$7.96M 1.56%
175,000
+5,000
+3% +$182K
2018 Q4
4 quarters
FOCL icon
29
EDAP TMS S.A.
FOCL
$197M
$7.91M 1.55%
1,785,000
+1,485,000
+495% +$6.97M
2019 Q3
1 quarter
TCDA
30
DELISTED
Tricida, Inc. Common Stock
TCDA
$7.3M 1.43%
194,000
-1,000
-0.5% -$37.3K
2018 Q3
5 quarters
DNTH icon
31
Dianthus Therapeutics
DNTH
$3.93B
$6.73M 1.32%
28,122
+4,059
+17% +$758K
2018 Q2
6 quarters
CRNX icon
32
DELISTED
Crinetics Pharmaceuticals
CRNX
$6.68M 1.31%
266,100
+59,100
+29% +$1.13M
2019 Q1
3 quarters
RARX
33
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$6.66M 1.31%
141,800
– –
2019 Q2
2 quarters
TGTX icon
34
TG Therapeutics
TGTX
$8.29B
$6.43M 1.26%
579,651
-32,849
-5% -$250K
2018 Q1
7 quarters
KYNB icon
35
Kyntra Bio
KYNB
$20.4M
$6.26M 1.23%
5,840
-160
-3% -$163K
2014 Q4
20 quarters
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$4.58M 0.9%
+760,000
New +$4.4M
2019 Q4
0 quarters
AQST icon
37
Aquestive Therapeutics
AQST
$482M
$4.3M 0.84%
+738,500
New +$3.84M
2019 Q4
0 quarters
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.26M 0.84%
+940,373
New +$3.44M
2019 Q4
0 quarters
RDUS icon
39
DELISTED
Radius Health, Inc.
RDUS
$3.39M 0.66%
168,000
+93,000
+124% +$2.26M
2019 Q3
1 quarter
QTRX icon
40
Quanterix
QTRX
$139M
$3.12M 0.61%
132,200
-52,800
-29% -$1.2M
2019 Q3
1 quarter
RYTM icon
41
Rhythm Pharmaceuticals
RYTM
$5.96B
$2.54M 0.5%
+110,500
New +$2.45M
2019 Q4
0 quarters
TELA icon
42
TELA Bio
TELA
$43.7M
$2.27M 0.44%
+175,000
New +$2.14M
2019 Q4
0 quarters
MGNX icon
43
MacroGenics
MGNX
$208M
$2.18M 0.43%
+200,500
New +$1.98M
2019 Q4
0 quarters
FENC icon
44
Fennec Pharmaceuticals
FENC
$350M
$78K 0.02%
+12,000
New +$64.5K
2019 Q4
0 quarters
TARA icon
45
Protara Therapeutics
TARA
$140M
$75K 0.01%
4,704
+3,354
+248% +$38.5K
2019 Q3
1 quarter
BLRX icon
46
BioLineRX
BLRX
$10.2M
$38K 0.01%
417
– –
2013 Q4
24 quarters
ASMB icon
47
Assembly Biosciences
ASMB
$408M
– –
-4,167
Closed -$492K –
CYTK icon
48
Cytokinetics
CYTK
$8.64B
– –
-650,000
Closed -$7.4M –
NXTC icon
49
NextCure
NXTC
$28.8M
– –
-7,083
Closed -$2.62M –
TVRD icon
50
Tvardi Therapeutics
TVRD
$13.3M
– –
-12,222
Closed -$8.04M –
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
TFA
Teamwork Financial Advisors San Antonio, Texas $1.1B AUM 39.98% 1-Year Est. Return

Opaleye Management's Q4 2019 Portfolio in Review

As of Q4 2019, Opaleye Management held 56 positions worth $510M, up 84% from $277M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $45.1M of net new capital in Q4 2019, opening 7 new positions and adding to 29 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Quanterix, an estimated $1.2M trimmed.

  • Opaleye Management's largest Q4 2019 buy was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.
  • Opaleye Management added most to Aptose Biosciences, Inc. in Q4 2019, an estimated $9.74M increase.
  • Opaleye Management's biggest Q4 2019 reduction was Quanterix, cutting an estimated $1.2M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q4 2019, selling an estimated $8.04M.
  • Opaleye Management's ten largest holdings make up 43% of its $510M portfolio in Q4 2019.
  • Opaleye Management opened 7 new positions and closed 9 in Q4 2019.
  • Opaleye Management's portfolio value rose 84% quarter-over-quarter to $510M.

Based on Opaleye Management's 13F filing for Q4 2019, filed 14 Feb 2020.